You can buy or sell DexCom and other stocks, options, ETFs, and crypto commission-free!
DexCom, Inc. Common Stock, also called DexCom, is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Read More Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share,and Mobile apps. The company was founded by John F. Burd in May 1999 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMay 7
See what the IHS Markit Score report has to say about Dexcom Inc.
Dexcom Inc NASDAQ/NGS:DXCM View full report here! Summary ETFs holding this stock are seeing positive inflows but are weakening Bearish sentiment is low Economic output in this company's sector is expanding Bearish sentiment Short interest | Positive Short interest is low for DXCM with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling e...
DexCom (DXCM) Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q1 2019 Earnings Call May. 01, 2019 , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the DexCom first-quarter 2019 earnings release conference call. My name is Adrianne, and I'll be your operator for today's call. [Operator instructions] Please note, this conference is being recorded. I'll now turn the call over to Matt Dolan. Matt Dolan, you may begin. Matt Dolan -- Vice P...
DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance
DexCom, Inc. DXCM reported adjusted loss of 5 cents per share in the first quarter of 2019, significantly narrower than the Zacks Consensus Estimate of a loss of 17 cents per share. Further, the figure was narrower than the year-ago quarter's loss of 32 cents per share. Total revenues surged 52.1% to $280.5 million on a year-over-year basis and also surpassed the Zacks Consensus Estimate by 14%. Rising volumes across all channels along with the increasing global awareness of the benefits of real-time CGM...
Expected Jul 31, After Hours